Fluciclovine (18f)
Axumin (fluciclovine f18) is a small molecule pharmaceutical. Fluciclovine f18 was first approved as Axumin on 2016-05-27. It has been approved in Europe to treat prostatic neoplasms and radionuclide imaging. Axumin's patents are valid until 2035-12-30 (FDA).
| Trade Name | Axumin |
|---|---|
| Common Name | Fluciclovine (18f) |
| Indication | prostatic neoplasms, radionuclide imaging |
| Drug Class | Vinca alkaloids |
